{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:05:44Z","timestamp":1780599944952,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00115-019-00813-y","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T11:03:55Z","timestamp":1570791835000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Die aktualisierte S3-Leitlinie Schizophrenie","Revised S3 guidelines on schizophrenia"],"prefix":"10.1007","volume":"91","author":[{"given":"Alkomiet","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wobrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Zielasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Gaebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"813_CR1","volume-title":"Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI), Fassung 2005\/2006 + Dom\u00e4ne 8","author":"M Beyer","year":"2008","unstructured":"Beyer\u00a0M, Geraedts\u00a0M, Gerlach\u00a0FM et al (2008) Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI), Fassung 2005\/2006 + Dom\u00e4ne 8. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF), \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin (\u00c4ZQ), Berlin, D\u00fcsseldorf"},{"key":"813_CR2","volume-title":"S3 Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2019","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2019) S3 Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. \nhttps:\/\/www.awmf.org\/leitlinien\/detail\/ll\/038-020.html\n\n. Zugegriffen: 04.08.2019"},{"key":"813_CR3","volume-title":"S3 Leitlinie Schizophrenie","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2019","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2019) S3 Leitlinie Schizophrenie. \nhttps:\/\/www.awmf.org\/leitlinien\/detail\/ll\/038-009.html\n\n. Zugegriffen: 02.08.2019"},{"key":"813_CR4","volume-title":"Behandlungsleitlinie Schizophrenie","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie und Nervenheilkunde","year":"1998","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie und Nervenheilkunde (1998) Behandlungsleitlinie Schizophrenie. Steinkopff, Heidelberg"},{"key":"813_CR5","volume-title":"S3 Leitlinie Schizophrenie Leitlinienreport","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2019","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2019) S3 Leitlinie Schizophrenie Leitlinienreport. \nhttps:\/\/www.awmf.org\/leitlinien\/detail\/ll\/038-009.html\n\n. Zugegriffen: 02.08.2019"},{"key":"813_CR6","volume-title":"S3 Leitlinie Verhinderung von Zwang: Pr\u00e4vention und Therapie aggressiven Verhaltens bei Erwachsenen","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2018","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2018) S3 Leitlinie Verhinderung von Zwang: Pr\u00e4vention und Therapie aggressiven Verhaltens bei Erwachsenen. \nhttps:\/\/www.awmf.org\/leitlinien\/detail\/ll\/038-022.html\n\n. Zugegriffen: 04.08.2019"},{"key":"813_CR7","volume-title":"S3 Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2013","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2013er) S3 Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen"},{"key":"813_CR8","series-title":"S3 Praxisleitlinien in Psychiatrie und Psychotherapie","volume-title":"Behandlungsleitlinie Schizophrenie","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde","year":"2006","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (2006) Behandlungsleitlinie Schizophrenie. S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd. 1. Steinkopff, Darmstadt"},{"key":"813_CR9","volume-title":"S3 Leitlinie Alkoholbezogene St\u00f6rungen: Screening, Diagnose und Behandlung","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2016","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2016) S3 Leitlinie Alkoholbezogene St\u00f6rungen: Screening, Diagnose und Behandlung. \nhttps:\/\/www.awmf.org\/leitlinien\/detail\/ll\/076-001.html\n\n. Zugegriffen: 04.08.2019"},{"key":"813_CR10","volume-title":"S3 Leitlinie Tabakkonsum (Rauchen), abh\u00e4ngiger und sch\u00e4dlicher: Screening, Diagnostik und Behandlung","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde","year":"2015","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (2015) S3 Leitlinie Tabakkonsum (Rauchen), abh\u00e4ngiger und sch\u00e4dlicher: Screening, Diagnostik und Behandlung. \nhttps:\/\/www.awmf.org\/leitlinien\/detail\/ll\/076-006.html\n\n. Zugegriffen: 04.08.2019"},{"key":"813_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00115-015-4357-y","volume":"86","author":"I Grossimlinghaus","year":"2015","unstructured":"Grossimlinghaus\u00a0I, Falkai\u00a0P, Gaebel\u00a0W et\u00a0al (2015) Assessment of quality indicators with routine data: presentation of a\u00a0feasibility test in ten specialist clinics for psychiatry and psychotherapy. Nervenarzt 86:1393\u20131399","journal-title":"Nervenarzt"},{"key":"813_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00115-017-0347-6","volume":"88","author":"I Grossimlinghaus","year":"2017","unstructured":"Grossimlinghaus\u00a0I, Hauth\u00a0I, Falkai\u00a0P et\u00a0al (2017) DGPPN recommendations on quality indicators for schizophrenia. Nervenarzt 88:779\u2013786","journal-title":"Nervenarzt"},{"key":"813_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes\u00a0OD, Mccutcheon\u00a0R, Agid\u00a0O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174:216\u2013229","journal-title":"Am J Psychiatry"},{"key":"813_CR14","volume-title":"Psychosis and schizophrenia in children and young people: recognition and management","author":"National Institute for Healt and Care Excellence (NICE)","year":"2013","unstructured":"National Institute for Healt and Care Excellence (NICE) (2013) Psychosis and schizophrenia in children and young people: recognition and management. \nhttps:\/\/www.nice.org.uk\/guidance\/cg155\/evidence\/full-guideline-pdf-6785647416\n\n. Zugegriffen: 02.08.2019"},{"key":"813_CR15","volume-title":"Psychosis and schizophrenia in adults: prevention and management","author":"National Institute for Healt and Care Excellence (NICE)","year":"2014","unstructured":"National Institute for Healt and Care Excellence (NICE) (2014) Psychosis and schizophrenia in adults: prevention and management. \nhttps:\/\/www.nice.org.uk\/guidance\/cg178\n\n. Zugegriffen: 02.08.2019"},{"key":"813_CR16","volume-title":"Violence and aggression: short-term management in mental health, health and community settings","author":"National Institute for Healt and Care Excellence (NICE)","year":"2015","unstructured":"National Institute for Healt and Care Excellence (NICE) (2015) Violence and aggression: short-term management in mental health, health and community settings. \nhttps:\/\/www.nice.org.uk\/guidance\/ng10\n\n. Zugegriffen: 02.08.2019"},{"key":"813_CR17","volume-title":"SIGN 131 \u2013 management of schizophrenia","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2013","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) (2013) SIGN 131 \u2013 management of schizophrenia. \nhttps:\/\/www.sign.ac.uk\/sign-131-management-of-schizophrenia.html\n\n. Zugegriffen: 02.08.2019"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-00813-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:18:39Z","timestamp":1602289119000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-00813-y"}},"subtitle":["Entwicklungsprozess und ausgew\u00e4hlte Empfehlungen","Developmental process and selected recommendations"],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-00813-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"11 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Hasan erhielt Beraterhonorare von Lundbeck, Otsuka, Janssen und Roche und hielt verg\u00fctete Vortr\u00e4ge f\u00fcr Lundbeck, Otsuka und Janssen. Er ist Herausgeber der WFSBP (World Federation of Societies of Biological Psychiatry) Leitlinie Schizophrenie. P.\u00a0Falkai erhielt Beraterhonorare von Janssen, Richter Pharma, Servier und Sage und hielt verg\u00fctete Vortr\u00e4ge f\u00fcr Otsuka, Lundbeck, Janssen und Richter Pharma. T.\u00a0Wobrock war Mitglied des Advisory Boards von Janssen Cilag und Otsuka\/Lundbeck und hielt verg\u00fctete Vortr\u00e4ge f\u00fcr Alpine Biomed, AstraZeneca, Bristol Myers Squibb, Eli Lilly, I3G, Glaxo-Smith-Kline, Janssen Cilag, Novartis, Lundbeck, Otsuka, Roche, Sanofi-Aventis, Pfizer und die Gesellschaft f\u00fcr medizinische Fortbildung mbH. Er erhielt fr\u00fcher Forschungsmittel von AstraZeneca, Cerbomed, I3G und der AOK. J.\u00a0Zielasek erhielt als Mitglied des Wissenschaftlichen Komitees des DGPPN-Kongresses finanzielle Unterst\u00fctzung von der DGPPN f\u00fcr die Teilnahme am Jahreskongress. W.\u00a0Gaebel Wolfgang Gaebel ist Mitglied der Lundbeck International Neuroscience Foundation (LINF). I.\u00a0Lehmann und B.\u00a0Janssen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}